DNA RNA and Cells
9 February 2013
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells6 February 2013
First Patient Treated in Genelux Phase I Trial With GL-ONC1 at Memorial Sloan Kettering Cancer Center5 February 2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia5 February 2013
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome4 February 2013
International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson’s Disease31 January 2013
Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors30 January 2013
RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program30 January 2013
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis28 January 2013
Oncolytics Biotech® Inc. Announces Positive REOLYSIN Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium23 January 2013
Mirna Therapeutics Presents Preclinical Data on Lead Product Candidate MRX34 at Keystone Conference11 January 2013
MESOBLAST’S NEOFUSE STEM CELL PRODUCT SHOWS POSITIVE RESULTS IN PHASE 2 LUMBAR SPINAL FUSION TRIAL10 January 2013
BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia in EuropeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports